Dr. Kalevi Kurkijärvi (65)
Chairman & CEO, Founding Partner
Kalevi is the founder and main owner of Innomedica. He is one of the pioneers of the Finnish biotech industry with more than 30 years of experience in the international business environment including sales & marketing, manufacturing, R&D, business development, corporate management, entrepreneurship and 10+ years of experience in private equity financing. Kalevi has a PhD in Biochemistry and Molecular Biology from the University of Turku. Additionally, he has completed the Management and Business Administration Program at Turku School of Economics and holds the Board Director Examination approved by the Chamber of Commerce.
Kalevi is Chairman & CEO of Biketex Oy, his family company in import-export trading. He is co-founder and former Executive Chairman of Bio Fund Mangement Oy, a biotech VC company. He has acted in several managerial positions at Perkin Elmer Wallac, most recently as Executive Vice President and Business Division Director. He was the CEO of Pharmacia Diagnostics Production. Kalevi has gained extensive administrative history and corporate development views as well as licensing, M&A and IPO experience of high tech companies by serving as a director or chairman in about 30 international companies such as FibroGen Inc., Paratek Pharmaceuticals Corp., Ark Therapeutics Corp., Biotie Therapies Oyj, Hytest Oy, Hormos Medical Oy, Rados Technology Oy, MAP Medical Technologies Oy, as well as many others.
Anna Kalmi,+358 10 235 0512
Senior Partner, Vice President, Japan Licensing
Anna is an expert in international licensing and business development. She has more than 15 years of experience in life sciences licensing & partnering between Japan and Europe/USA. Anna has worked with both pharmaceutical and medtech companies and she has extensive experience in oncology, inflammation, respiratory, CNS, dermatology, women’s health, ophthalmic, biomaterial, nutraceutical and drug delivery technology products. Anna has a MSc in physics. As a native of Japan, she understands the market environment and cultural features of the Japanese market.
Dr. Johanna Furuhjelm,+46 76 583 2992
Partner, Manager, Market Intelligence
Johanna is an expert in analyzing the market potential of science based inventions. She has a deep understanding of the European biotech and healthcare market with an emphasis on diagnostics, and is responsible for Innomedica’s market intelligence services. Johanna has a PhD in Genetics and Biosciences with emphasis on cellular and molecular biology. Before joining Innomedica in 2007 she conducted research on a postdoctoral level, gaining experience in cell biology, molecular biology, virology, genetics and microbiology.
Yoritsugu Noro,+358 10 235 0510
Senior Advisor, Japan
Mr Noro has extensive experience at a senior level in the Japanese Pharma Industry. He was formerly engaged in a senior position at Taisho Pharmaceuticals, one of the major Japanese pharma with both Rx and OTC products. Mr Noro has an impressive track record of succesful licensing deals, international sales and business development. Mr Noro supports Innomedica’s clients in Japan.
Matti Juvonen,+358 10 235 0513
Manager, Business Development
Matti specializes in international sales and business development in life sciences, especially in the field of laboratory, medical equipment and in vitro diagnostics. Matti has 20 years of experience in different positions in sales and marketing. He is an experienced door opener and business accelerator both in distributor and direct sales operations. During the years Matti has gained vast experience with both SMEs who are at the beginning of their operations and larger companies who are seeking new growth. Matti has worked extensively with European, North American and Middle-Eastern markets. Matti has an MSc in economics.
Dr. Heikki Laurila,+358 400 506 794
Heikki has firm formal background in biotechnology (microbiology, zoology, pharmacology, process engineering etc with PhD from ETH) as well as over 20 years consulting history in strategy, process re-engineering, M&A, financing, startups and a MBA from IMD. Many projects have led to deep consulting knowledge in industrial biotechnology and global health care businesses.